Oyster Mushroom Cardiovascular Health
0–342 mg/kg
The full published range for lovastatin in dried Pleurotus ostreatus, from not detected to 342 mg/kg dry weight. The two studies that explicitly used mass spectrometry sit at the bottom of that range.
Lam & Okello 2015; Svoboda et al. 2017; Piskov et al. 2018
1995
Year lovastatin was first confirmed present in Pleurotus fruiting bodies
2 of 2
Mass-spectrometry studies that found essentially no lovastatin in oyster mushroom
~90 kg
Fresh mushroom per day to reach a 10 mg statin dose at the highest LC-MS concentration on record
Lam & Okello 2015; Svoboda et al. 2017; Piskov et al. 2018
View as image ↗Oyster mushrooms have a genuinely remarkable claim attached to them: that they contain lovastatin, the exact molecule sold as a prescription cholesterol drug under brand names like Mevacor. Not a similar compound. Not a functional analog. The same molecule, blocking the same enzyme. That claim is true, and it was confirmed in a peer-reviewed journal in 1995.
The question this article addresses is the obvious follow-up, and it turns out to be far harder to answer than the first one. When you eat an oyster mushroom, how much lovastatin are you actually getting? Search for that number and you will find one quoted with great confidence. Go and read the studies it supposedly comes from, and the confidence evaporates. Oyster mushrooms are among the best-studied functional mushrooms for cholesterol and cardiovascular health, and for broader background on oyster mushroom (Pleurotus ostreatus) that full profile covers the wider picture. This article does something narrower: it opens each published measurement and reports what is actually inside it.
If you only read one thing
There is no reliable published figure for how much lovastatin is in an oyster mushroom. Reported values span from not detected to 342 mg/kg dry weight, and the disagreement tracks the analytical method rather than the mushroom: the two studies that explicitly used mass spectrometry both found essentially none in Pleurotus ostreatus, while the highest oyster value came from a UV-absorbance method that later work showed is invalidated by co-absorbing mushroom compounds. Whichever figure you accept, none of them puts a realistic plate of mushrooms anywhere near a 10 mg prescription statin dose.
Key Takeaways
- Lovastatin is genuinely present in Pleurotus ostreatus fruiting bodies — Gunde-Cimerman and Cimerman confirmed this in 1995 — but that paper established presence and tissue distribution, not a dietary quantity
- Published values for P. ostreatus span from "not detected" to 342 mg/kg dry weight, a range that cannot be reconciled by biology alone
- Lam and Okello's 2015 analysis of raw and processed P. ostreatus, frequently cited as the source of a specific lovastatin figure, reports the opposite: "Lovastatin was not detected in this study"
- Svoboda and colleagues, using a validated matrix-effect-free MISPE-UHPLC-MS/MS method, found "low or null" lovastatin in three retail oyster mushroom samples
- Tsiantas and colleagues showed in 2021 that UV-Vis methods give invalid lovastatin results in mushroom matrices because other constituents absorb in the same range; by validated LC-MS, the highest of three species tested was Agaricus bisporus at 1.39 mg/kg — not an oyster
- The highest fruiting-body values in multi-species surveys belong to shimeji (628 mg/kg) and lion's mane (14.38 mg/kg), not to Pleurotus
- Even taking the single highest oyster figure on record at face value, clinical trials showing cholesterol reduction from oyster mushrooms cannot be explained by lovastatin dose alone
The Number You've Probably Seen
If you have read about oyster mushrooms and cholesterol, you have probably encountered a confident, specific figure: something in the region of a few milligrams of lovastatin per 100 grams, often attributed to a 2015 paper by Lam and Okello in the International Journal of Medicinal Mushrooms. Consumer articles cite it. Supplement pages cite it. It has the texture of a settled fact.
It is not one. Lam and Okello did analyze raw and processed P. ostreatus, and they did look for lovastatin. Their abstract states the result in six words: "Lovastatin was not detected in this study."[1] What they successfully quantified was β-glucan at 23.9% of dry matter, total polyphenols at 487.12 mg gallic acid equivalent per 100 g, dry matter content of 8%, and three separate measures of antioxidant activity. Lovastatin returned nothing above their detection limit.
Citation Provenance
Where the Confident Number Comes From
The claim
“Oyster mushrooms contain a specific, known quantity of lovastatin, established by direct analysis and traceable to Lam & Okello's 2015 study.”
A widely-mirrored secondary claim that Pleurotus ostreatus contains 'up to 2.8% lovastatin on a dry weight basis' circulates through encyclopedia-derived consumer pages, which cite no primary study for it at all. Retellings then pair a specific milligram figure with the name of a primary paper, and the pairing is what gives the number its apparent provenance.
What research shows
UnsupportedThe paper most often named as the source reports non-detection. Lam & Okello (2015) measured lovastatin in raw P. ostreatus and found none above their detection limit.
This does not mean oyster mushrooms contain zero lovastatin — Gunde-Cimerman and Cimerman demonstrated in 1995 that the molecule is genuinely present in Pleurotus fruiting bodies. It means the specific, quotable dietary quantity that circulates online has no verifiable primary source behind it, and the paper it is credited to says the opposite.
Lam & Okello 2015 [1]; Gunde-Cimerman & Cimerman 1995 [2]
Lam & Okello (2015) · International Journal of Medicinal Mushrooms
- Population
- Raw and processed Pleurotus ostreatus samples, plus mushroom rolls made from blanched mushrooms and blanching water
- Intervention
- Quantification of lovastatin, β-glucan, total polyphenols and antioxidant activity; blanching as the processing variable
- Finding
- Lovastatin was not detected. β-glucan (23.9% of dry matter) was not significantly affected by blanching, while dry matter, polyphenols and all three antioxidant measures fell significantly. Re-adding the blanching water during roll production recovered much of what blanching removed.
narrow-scope A careful compositional study that is routinely miscited. Its actual lovastatin result is a non-detection, and its genuinely useful findings are about β-glucan and polyphenol retention.
Lam & Okello, Int J Med Mushrooms, 2015 [1]
What the Most Rigorous Measurements Found
Non-detection in a single study could just mean an insensitive method. So the more informative question is what happens when researchers bring the best available analytical chemistry to the problem.
Svoboda and colleagues built a method specifically for this class of problem: determining lovastatin in food matrices without the matrix itself corrupting the measurement.[8] Their approach used molecularly imprinted solid-phase extraction coupled to UHPLC-MS/MS, validated for precision, accuracy, linearity, limits of detection and quantification, and — critically — for matrix effects, which they eliminated entirely. They then applied it to real retail food: three mushroom samples and fifteen tea samples bought in Czech food stores and tearooms. The finding on the mushrooms was that a low or null amount of lovastatin was present.
Tsiantas and colleagues approached it from the methodological side.[5] They compared UV-Vis spectrometry against liquid chromatography-mass spectrometry for quantifying lovastatin and ergothioneine across Agaricus bisporus, Pleurotus ostreatus and P. citrinopileatus, grown on several different substrates. Their conclusion was blunt: the validated LC-MS methods are the technique of choice, while UV-Vis methods were "hindered due to co-absorbance of different constituents, resulting in invalid results." By LC-MS, the highest lovastatin content among all three species was in A. bisporus — the ordinary button mushroom — at 1.39 ± 0.014 mg/kg of dry sample. That is 0.139 mg per 100 g of dried mushroom, and it belongs to a species nobody markets as a natural statin.
Every Published Number, Side by Side
The Disagreement Tracks the Method, Not the Mushroom
Each bar is one reported measurement of lovastatin in dried mushroom tissue. Where a study states its detection method in the record, it is badged. The two studies that explicitly used mass spectrometry found essentially none; the single highest oyster figure comes from a UV-absorbance method. Note the log scale — each gridline is 10× the last.
mg/kg dry weight (log scale)
Read the badges, not the bars: three of the four highest values on this chart belong to species that are not oyster mushrooms at all, and the tallest oyster bar was produced by measuring UV absorbance at 295 nm — the class of method Tsiantas and colleagues found to be invalidated by co-absorbing mushroom constituents. The two studies using mass spectrometry, the technique that physically separates lovastatin before measuring it, both returned essentially nothing from P. ostreatus.
Sources: Lam & Okello 2015 [1] (lovastatin not detected in raw P. ostreatus); Tsiantas et al. 2021 [5] (A. bisporus 1.39 ± 0.014 mg/kg, the highest of three species by validated LC-MS); Lo et al. 2012 [7] (628.05 mg/kg fruiting-body ceiling across 19 species, H. marmoreus); Svoboda et al. 2017 [8] (low or null in three retail oyster samples by MISPE-UHPLC-MS/MS); Piskov et al. 2018 [9] (342 ± 9.0 mg/kg freeze-dried vs 190 ± 6.0 mg/kg hot-air dried P. ostreatus, optical density at 295 nm); Cohen et al. 2014 [10] (14.38 µg/g fruiting-body ceiling across 12 species, H. erinaceus). Bar lengths are exact on the log axis. Survey ceilings are shown to bound the published range and are labeled by species; they are not oyster values.
Why the Published Numbers Disagree
The variation across the literature is not random noise, and it is not simply the natural variability of a living organism. Three distinct things are going on, and only one of them is biology.
The species get swapped
The eye-catching maxima quoted for "mushroom lovastatin" frequently belong to species that are not oyster mushrooms. Lo and colleagues surveyed lovastatin, GABA and ergothioneine across 15 fruiting bodies and 9 mycelia spanning 19 species.[7] The highest fruiting-body lovastatin content in that survey was 628.05 mg/kg, and it was Hypsizygus marmoreus — shimeji. The highest mycelial value, 1438.42 mg/kg, was Morchella esculenta, a morel. Cohen and colleagues ran a comparable survey across 15 strains from 12 species and found the highest fruiting-body lovastatin in Hericium erinaceus at 14.38 μg/g, with Ganoderma lucidum second at 11.54 μg/g.[10] Lion's mane and reishi, not oyster. When a survey ceiling gets quoted without its species label, an oyster mushroom inherits a number it never earned.
Culture yield is not food content
Several of the most-cited lovastatin papers on Pleurotus are not measuring the mushroom on your plate at all. Alarcón and colleagues cultured P. ostreatus strains in liquid medium and on wheat straw and compared lovastatin yields.[3] Alarcón and Aguila then showed that the carbon and nitrogen sources and the C:N ratio of the medium influence lovastatin production, with the maximum yield obtained in a medium containing organic nitrogen.[4] Atli and colleagues optimized submerged fermentation conditions and reached 114.82 mg/L of broth after six days, roughly 50 times the unoptimized yield.[11]
These are real, well-conducted studies, and they establish something genuinely important: lovastatin output from Pleurotus is exquisitely sensitive to growing conditions. But 114.82 mg per liter of stirred liquid culture is a bioprocess number in different units and a different matrix. It says nothing directly about milligrams per kilogram of the fruiting body you would sauté.
The method decides the answer
The third source is the one Tsiantas quantified, and on current evidence it is the largest. A UV-absorbance reading and a validated LC-MS reading of the same mushroom are not two estimates of one truth with some scatter between them; one of them is measuring lovastatin and the other is measuring lovastatin plus whatever else absorbs at that wavelength. This is why the literature contains both "not detected" and "342 mg/kg" for the same species, and why averaging across the published range would be a mistake rather than a compromise.
What 1995 Actually Established
The foundational paper deserves to be read for what it says rather than what has been built on top of it. Gunde-Cimerman and Cimerman reported in 1995 that fruiting bodies of Pleurotus ostreatus contain a competitive inhibitor of HMG-CoA reductase, and identified it as lovastatin.[2] They tracked its appearance through the development of the fruiting body and looked at the vegetative mycelium, the primordia, and different parts of sporocarps at different sizes. They found less lovastatin in the stipes than in the caps, and reported it in the gills and basidiospores at mature stages.
That is a presence-and-distribution finding, and it is a solid one. HMG-CoA reductase is the enzyme controlling a key early step in the liver's cholesterol manufacture, and inhibiting it is how every statin drug lowers LDL. Oyster mushrooms really do make that inhibitor through their own secondary metabolism. What the paper does not provide — and was not designed to provide — is a dietary concentration you could use to calculate a dose. Thirty years later, no study using a matrix-controlled mass-spectrometric method has supplied one either.
Processing: the One Direct Comparison
The effect of heat and drying on mushroom lovastatin is thinly studied, but it is not entirely unstudied. Piskov and colleagues compared two drying methods on P. ostreatus fruiting bodies — freeze-drying sublimation against dry-air drying — and measured lovastatin in both.[9] Freeze-dried samples contained 342 ± 9.0 mg/kg; hot-air dried samples contained 190 ± 6.0 mg/kg, a significant difference. Antioxidant activity followed the same pattern, at 3.83 ± 0.02 against 2.0 ± 0.03 mmol/100 g. Freeze-drying also better preserved the mushrooms' cell structure and their soluble protein and polysaccharide fractions.
Two things are worth holding at once here. The relative result is credible and useful: gentler dehydration preserved more of whatever was being measured, which is the expected direction and is corroborated by the parallel antioxidant finding. But Piskov's team quantified lovastatin by optical density of hydro-alcohol extracts at 295 nm — a UV-absorbance approach, precisely the class of method Tsiantas and colleagues found to be invalidated by co-absorbing mushroom constituents.[5] The 342 mg/kg figure is best read as an upper bound rather than a concentration. This article's sibling piece on cooking and lovastatin stability in oyster mushrooms works through the heat question in more detail.
For what it is worth on the beta-glucan side, Lam and Okello's blanching data is unambiguous and does not depend on the contested measurement: β-glucan content was not significantly affected by blanching, while polyphenols and antioxidant activity fell — and re-adding the blanching water recovered much of the loss, indicating the compounds leached out rather than degrading.[1]
The Dose Math
Whatever number you choose to believe, it is worth running the arithmetic, because the conclusion turns out to be robust across the entire published range. The lowest starting dose of pharmaceutical lovastatin is 10 mg per day. Using Lam and Okello's measured 8% dry matter content to convert to fresh weight:
| Source figure | Concentration (dry) | Dry mushroom for 10 mg | Fresh mushroom for 10 mg |
|---|---|---|---|
| Piskov 2018, freeze-dried P. ostreatus (UV method) | 342 mg/kg | ~29 g | ~370 g |
| Cohen 2014, highest of 12 species (H. erinaceus) | 14.38 mg/kg | ~700 g | ~8.7 kg |
| Tsiantas 2021, highest of 3 species by LC-MS (A. bisporus) | 1.39 mg/kg | ~7.2 kg | ~90 kg |
| Lam & Okello 2015 / Svoboda 2017, P. ostreatus | Not detected / low or null | Undefined | Undefined |
The single most favorable figure in the literature — an upper-bound UV measurement of freeze-dried mushroom — would require roughly 370 g of fresh oyster mushroom daily to match the smallest prescription dose, sustained indefinitely, assuming the lovastatin survives cooking and is absorbed as efficiently as the pharmaceutical lactone, neither of which has been demonstrated. Every other credible figure pushes the requirement into kilograms or leaves it undefined. There is no reading of this literature in which a plate of oyster mushrooms is a statin.
Food vs Pharmaceutical
Lovastatin: Mushroom vs Prescription
What research used
Not established for food
Oral, whole food
Daily dietary intake · Not defined by any trial
No study using a matrix-controlled mass-spectrometric method has established a reliable lovastatin concentration in Pleurotus ostreatus. The two that applied one reported non-detection or 'low or null'.
What supplements sell
10–80 mg/day
Oral tablet
Once daily
Prescription lovastatin (e.g. Mevacor and generics), titrated by a prescriber against lipid response
The gap is not a matter of eating more mushrooms. At the most generous published concentration the requirement is roughly 370 g of fresh mushroom daily to reach the lowest prescription dose; at the most rigorously measured concentration it is on the order of 90 kg. Oyster mushroom supplements are not standardized to a stated lovastatin content, so they do not close this gap either.
- *Every dietary figure here is calculated from dry-weight concentrations converted at Lam & Okello's measured 8% dry matter
- *Bioavailability of lovastatin from whole mushroom tissue has not been characterized and is assumed, not demonstrated
- *The highest oyster figure derives from a UV-absorbance method shown to be unreliable in mushroom matrices
Lam & Okello 2015 [1]; Tsiantas 2021 [5]; Svoboda 2017 [8]; Piskov 2018 [9]; Cohen 2014 [10]
Then Why Do the Trials Show an Effect?
Here is the part that keeps the topic interesting rather than merely debunked. Oyster mushrooms do appear to move lipid markers in humans, and the lovastatin content — on any reading of the evidence above — is nowhere near sufficient to explain it.
Khatun and colleagues recruited 89 diabetic subjects at BIRDEM hospital and ran a 24-day protocol structured as seven days with mushroom, seven days without, then seven days with mushroom again, with measurements at each boundary.[6] Thirty participants completed the full protocol. Mushroom consumption significantly reduced systolic and diastolic blood pressure, fasting and two-hour post-breakfast plasma glucose, total cholesterol and triglycerides, with no significant change in weight or HDL, and no evidence of liver or kidney toxicity. When mushroom was withdrawn, diastolic blood pressure, both glucose measures, total cholesterol and triglycerides all rose significantly again; restarting it reduced them again.
That withdrawal-and-rechallenge structure is the most valuable feature of the trial, because each participant serves as their own control across the reversal. It is also a small completer sample over a short period, and the report does not state a lovastatin dose — so it demonstrates an effect of eating mushrooms, not an effect of a quantified statin exposure.
- Compound identified in tissuecompleted
Lovastatin confirmed present in P. ostreatus fruiting bodies with tissue-level distribution mapped (Gunde-Cimerman & Cimerman 1995)
- Animal lipid modelscompleted
Oyster mushroom extract lowered lipids in hypercholesterolemic rats — but chrysin, a different constituent, outperformed the whole extract (Anandhi et al. 2013)
- Small human trial of the whole mushroomcompleted
24-day withdrawal-and-rechallenge protocol, 30 completers, significant reductions in glucose, blood pressure, total cholesterol and triglycerides (Khatun et al. 2007)
- Reliable quantification of dietary exposurecurrent
Unresolved, and blocking everything above it. Matrix-controlled mass spectrometry returns non-detection or 'low or null'; the higher figures come from methods shown to be invalid in mushroom matrices
- RCT isolating the lovastatin contributionmissing
No trial has separated a lovastatin contribution from beta-glucan and other constituents in whole oyster mushroom
- Meta-analysis of dietary lovastatinmissing
Not possible without reliable exposure quantification
The unusual shape of this evidence base is that the human trial evidence is further along than the analytical chemistry underneath it. We have a small but internally-controlled human trial showing an effect, and no dependable measurement of the compound that effect is popularly attributed to.
Gunde-Cimerman & Cimerman 1995 [2]; Khatun et al. 2007 [6]; Svoboda 2017 [8]; Anandhi et al. 2013 [12]
The most parsimonious explanation is that lovastatin is not the main actor. Oyster mushrooms contain substantial β-glucans — Lam and Okello measured 23.9% of dry matter — and β-glucans are soluble fibers that bind bile acids in the gut.[1] Bile acids are manufactured from cholesterol. When they are sequestered and excreted rather than reabsorbed, the liver must draw on circulating cholesterol to make more, and LDL falls through a route that has nothing to do with HMG-CoA reductase. This is the same well-established mechanism behind oat β-glucan's cardiovascular reputation, and unlike the lovastatin content, the β-glucan content of oyster mushrooms is measured consistently and survives blanching.
There is direct experimental support for the idea that the interesting molecule is not lovastatin. Anandhi and colleagues tested an ethanolic extract of P. ostreatus against chrysin, one of its constituents, in hypercholesterolemic rats, with pharmaceutical lovastatin as the reference drug.[12] Chrysin outperformed the whole mushroom extract and approached the effect of the reference statin. If the extract's activity were principally lovastatin, an isolated flavonoid should not have beaten it.
King oyster mushroom (Pleurotus eryngii) shows a related pattern in its bioactive compound profile, sharing the genus and the biosynthetic pathway. Shiitake operates differently again, through eritadenine, a nucleoside acting on SAH hydrolase rather than HMG-CoA reductase. For the human data specifically, the review of clinical evidence on oyster mushrooms and LDL reduction covers trial designs and doses, and the oyster mushroom heart health review covers blood pressure and endothelial endpoints beyond cholesterol.
Medication Safety
CriticalOyster Mushrooms Are Not a Statin Substitute
Concern
Because oyster mushrooms genuinely contain the same molecule as a prescription statin, some readers conclude that eating them can replace or reduce a prescribed statin dose. Discontinuing or reducing a statin without medical supervision carries a real cardiovascular risk, and nothing in this literature supports doing so.
What the research says
No study has established a reliable lovastatin concentration in oyster mushrooms, and every calculated dietary equivalent falls far short of the lowest prescription dose. Oyster mushrooms may reasonably be eaten as part of a cardioprotective diet; they cannot be dosed as a drug.
Particularly relevant for: Anyone currently prescribed a statin or other lipid-lowering medication, and anyone with diagnosed hyperlipidemia or cardiovascular disease
What to do
Do not change a prescribed medication based on mushroom intake. Discuss any dietary strategy for cholesterol with the prescribing clinician, who can measure whether it is working.
Lam & Okello 2015 [1]; Svoboda 2017 [8]; Tsiantas 2021 [5]
This article is research education, not medical advice, and nothing in it should be used to start, stop or adjust any medication.
The Bottom Line
Lovastatin is genuinely present in oyster mushrooms, but there is no dependable published figure for how much. Reported values for Pleurotus ostreatus run from not detected to 342 mg/kg dry weight, and the spread is driven by analytical method rather than biology: the two studies that explicitly used mass spectrometry found essentially none, while the highest oyster value came from a UV-absorbance technique that later work showed is invalidated by co-absorbing mushroom compounds. The frequently-quoted specific figure has no traceable primary source and is often credited to a paper that reports non-detection. Across the entire published range, no realistic quantity of oyster mushroom approaches the lowest prescription statin dose. Human trials do show lipid and blood-pressure improvements from eating oyster mushrooms, but the more plausible explanation is beta-glucan-mediated bile acid sequestration and other constituents such as chrysin, not a statin dose delivered by food.
Frequently Asked Questions
Sources & References
- 1RTHM-00384·Lam, Yu Shan et al. (2015). “Determination of Lovastatin, β-glucan, Total Polyphenols, and Antioxidant Activity in Raw and Processed Oyster Culinary-Medicinal Mushroom, Pleurotus ostreatus (Higher Basidiomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 2RTHM-00016·Gunde-Cimerman, N et al. (1995). “Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin..” Experimental mycology.Study breakdown →PubMed →↩
- 3RTHM-00054·Alarcón, Julio et al. (2003). “Production and purification of statins from Pleurotus ostreatus (Basidiomycetes) strains..” Zeitschrift fur Naturforschung. C.Study breakdown →PubMed →↩
- 4RTHM-00091·Alarcón, Julio et al. (2006). “Lovastatin production by Pleurotus ostreatus: effects of the C:N ratio..” Zeitschrift fur Naturforschung. C.Study breakdown →PubMed →↩
- 5RTHM-00725·Tsiantas, Konstantinos et al. (2021). “On the Identification and Quantification of Ergothioneine and Lovastatin in Various Mushroom Species: Assets and Challenges of Different Analytical Approaches..” Molecules (Basel.Study breakdown →PubMed →↩
- 6RTHM-00115·Khatun, K et al. (2007). “Oyster mushroom reduced blood glucose and cholesterol in diabetic subjects..” Mymensingh medical journal : MMJ.Study breakdown →PubMed →↩
- 7RTHM-00256·Lo, Yu-Chang et al. (2012). “Comparative study of contents of several bioactive components in fruiting bodies and mycelia of culinary-medicinal mushrooms..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 8RTHM-02287·Svoboda, Pavel et al. (2017). “Development of matrix effect-free MISPE-UHPLC-MS/MS method for determination of lovastatin in Pu-erh tea, oyster mushroom, and red yeast rice..” Journal of pharmaceutical and biomedical analysis.Study breakdown →PubMed →↩
- 9RTHM-02288·Piskov, S I et al. (2018). “The influence of the drying method for food properties and hypolipidemic potential of oyster mushrooms (Pleurotus ostreatus)..” Voprosy pitaniia.Study breakdown →PubMed →↩
- 10RTHM-02289·Cohen, Nachshol et al. (2014). “Chemical composition and nutritional and medicinal value of fruit bodies and submerged cultured mycelia of culinary-medicinal higher Basidiomycetes mushrooms..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 11RTHM-00277·Atli, Burcu et al. (2013). “Optimization of submerged fermentation conditions for lovastatin production by the culinary-medicinal oyster mushroom, Pleurotus ostreatus (Higher Basidiomycetes)..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 12RTHM-00508·Anandhi, Ramalingam et al. (2013). “Antihypercholesterolemic and antioxidative effects of an extract of the oyster mushroom, Pleurotus ostreatus, and its major constituent, chrysin, in Triton WR-1339-induced hypercholesterolemic rats..” Journal of physiology and biochemistry.Study breakdown →PubMed →↩